Proteomic analysis of cell lines to identify the irinotecan resistance proteins

Journal of Biosciences

Volumn 35, Issue 4, 2010, Pages 557-564

  Peng, Xing Chen ^a   Gong, Feng Ming ^a   Wei, Meng ^a   Chen, Xi ^a   Chen, Ye ^a   Cheng, Ke ^a   Gao, Feng ^a   Xu, Feng ^a   Bi, Feng ^a   Liu, Ji Yan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

2 DE; Colon cancer; drug resistance; irinotecan; proteomics

Indexed keywords

ACTIN; ACTIN LIKE PROTEIN 6A; ALDEHYDE REDUCTASE; ALPHA CRYSTALLIN; BETA ENOLASE; CELLULAR RETINOL BINDING PROTEIN 1; COFILIN 1; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE A; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; INORGANIC PYROPHOSPHATASE; IRINOTECAN; NUCLEOSIDE DIPHOSPHATE KINASE A; PEPTIDYLPROLYL ISOMERASE; PEROXIREDOXIN 4; SERUM ALBUMIN; STATHMIN; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

CANCER; CHEMORECEPTION; CHEMOTHERAPY; DRUG RESISTANCE; PROTEIN; PROTEOMICS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DOWN REGULATION; ELECTRON TRANSPORT; ELECTROSPRAY MASS SPECTROMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEOMICS; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; VITAMIN METABOLISM; WESTERN BLOTTING;

ALDEHYDE REDUCTASE; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR SEQUENCE DATA; PRODRUGS; PROTEOME; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 78651311728     PISSN: 02505991     EISSN: 02505991     Source Type: Journal    
DOI: 10.1007/s12038-010-0064-9     Document Type: Article

References (31)

1. A. P. Arrigo S. Simon B. Gibert C. Kretz-Remy M. Nivon A. Czekalla D. Guillet M. Moulin C. Diaz-Latoud P. Vicart 2007 Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets FEBS Lett. 581 3665 3674 1:CAS:528:DC%2BD2sXotlaisLw%3D 10.1016/j.febslet.2007.04.033 17467701 (Pubitemid 47086314)
2. R. Chen S. Pan T. A. Brentnall R. Aebersold 2005 Proteomic profiling of pancreatic cancer for biomarker discovery Mol. Cell Proteomics 4 523 533 1:CAS:528:DC%2BD2MXjtFCisb8%3D 10.1074/mcp.R500004-MCP200 15684406 (Pubitemid 40590569)
3. D. Flagiello F. Apiou A. Gibaud M. F. Poupon B. Dutrillaux B. Malfoy 1997 Assignment of the genes for cellular retinoic acid binding protein 1 (CRABP1) and 2 (CRABP2) to human chromosome band 15q24 and 1q21.3, respectively, by in situ hybridization Cytogenet. Cell Genet. 76 17 18 1:CAS:528:DyaK2sXjsVSnurY%3D 10.1159/000134502 9154115
4. G. L. Forrest B. Gonzalez 2000 Carbonyl reductase Chem. Biol. Interact. 129 2140 10.1016/S0009-2797(00)00196-4 (Pubitemid 32061052)
5. R. M. Goldberg 2006 Therapy for metastatic colorectal cancer Oncologist 11 981 987 1:CAS:528:DC%2BD28XhtFOrsb3P 10.1634/theoncologist.11-9-981 17030638 (Pubitemid 44564805)
6. G. Hütter P. Sinha 2001 Proteomics for studying cancer cells and the development of chemoresistance Proteomics 1 1233 1248 10.1002/1615-9861(200110) 1:10<1233::AID-PROT1233>3.0.CO;2-2 11721635
7. A. Jemal R. Siegel E. Ward Y. Hao J. Xu M. J. Thun 2009 Cancer statistics, 2009 CA-Cancer J. Clin. 59 225 249 10.3322/caac.20006 19474385
8. Y. Jin T. M. Penning 2007 Aldo-keto reductases and bioactivation/ detoxication Annu. Rev. Pharmacol. Toxicol. 47 263 292 1:CAS:528: DC%2BD2sXit1alt7g%3D 10.1146/annurev.pharmtox.47.120505.105337 16970545
9. Judson L K, William P H and Adrience C S 2004 Molecular analysis of alpha B-crystallin in human malignant glioma cell populations; AACR Meeting #2263
10. H. Kelly R. M. Goldberg 2005 Systemic therapy for metastatic colorectal cancer: current options, current evidence J. Clin. Oncol. 23 4553 4560 1:CAS:528:DC%2BD2MXnsl2ksLs%3D 10.1200/JCO.2005.17.749 16002847 (Pubitemid 46196586)
11. M. J. Kuffel J. M. Reid M. M. Ames 1992 Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture Cancer Chemother. Pharmacol. 30 51 57 1:CAS:528:DyaK38XkvVejtr0%3D 10.1007/BF00686485 1586980
12. H. Lage 2003 ABC-transporters: implications on drug resistance from microorganisms to human cancers Int. J. Antimicrob. Agents 22 188 199 1:CAS:528:DC%2BD3sXnt1yqur4%3D 10.1016/S0924-8579(03)00203-6 13678820 (Pubitemid 37103199)
13. X. Li B. J. Cusack J. R. J. Boucek P. S. Mushlin T. B. Bledsoe D. E. Brenner R. D. Olson 1991 Effects of daunorubicin and its primary metabolite, daunorubicinol, on cardiac contractility and calcium loading of sarcoplasmic reticulum FASEB J. 5 A1395
14. S. Licata A. Saponiero A. Mordente G. Minotti 2000 Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction Chem. Res. Toxicol. 13 414 420 1:CAS:528:DC%2BD3cXitlyltLk%3D 10.1021/tx000013q 10813659 (Pubitemid 30327162)
15. V. Ling 1997 Multidrug resistance: molecular mechanisms and clinical relevance Cancer Chemother. Pharmacol. Suppl. 40 38 10.1007/s002800050622 (Pubitemid 27160958)
16. P. Mariann S. Michael H. Christoph K. Lutz M. Edmund 2007 Increased resistance of tumor cells to daunorubicin after transfection of CDNAs coding for anthracycline inactivating enzymes Cancer Lett. 255 49 56 10.1016/j.canlet. 2007.03.018 (Pubitemid 47212606)
17. T. Matsunaga S. Shintani A. Hara 2006 Multiplicity of mammalian reductases for xenobiotic carbonyl compounds Drug Metab. Pharmacokinet. 21 118 10.2133/dmpk.21.1
18. A. Mordente G. Minotti G. E. Martorana A. Silvestrini B. Giardina E. Meucci 2003 Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications Biochem. Pharmacol. 66 989 998 1:CAS:528:DC%2BD3sXntVCgtr0%3D 10.1016/S0006-2952(03) 00442-8 12963485 (Pubitemid 37086708)
19. H. Ohara Y. Miyabe Y. Deyashiki K. Matsuura A. Hara 1995 Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver Biochem. Pharmacol. 50 221 227 1:CAS:528: DyaK2MXnt1Sktb8%3D 10.1016/0006-2952(95)00124-I 7632166
20. R. D. Olson P. S. Mushlin D. E. Brenner S. Fleischer B. J. Cusack B. K. Chang R. J. Boucek Jr 1988 Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol Proc. Natl. Acad. Sci. USA 85 3585 3589 1:CAS:528:DyaL1cXktFKlurc%3D 10.1073/pnas.85.10.3585 2897122
21. R. P. Perez 1998 Cellular and molecular determinants of cisplatin resistance Eur. J. Cancer 34 1535 1542 1:CAS:528:DyaK1cXmvVSku7c%3D 10.1016/S0959-8049(98)00227-5 9893624 (Pubitemid 28446333)
22. Y. Pommier P. Pourquier Y. Fan D. Strumberg 1998 Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme Biochim. Biophys. Acta 1400 83 105 1:CAS:528:DyaK1cXmtFWisr4%3D 9748515
23. B. Schott J. Robert 1989 Comparative activity of anthracycline 13-hydroxymetabolites against rat glioblastoma cells in culture Biochem. Pharmacol. 38 4069 4074 1:CAS:528:DyaK3cXmvFGjtQ%3D%3D 10.1016/0006-2952(89) 90688-6 2597184 (Pubitemid 20008745)
24. P. Sinha G. Hütter E. Kottgen M. Dietel D. Schadendorf H. Lage 1999 Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-σ(stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas Electrophoresis 20 2952 2960 1:CAS:528:DyaK1MXmvFahtrg%3D 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H 10546833 (Pubitemid 29517227)
25. J. G. Slatter P. Su J. P. Sams L. J. Schaaf L. C. Wienkers 1997 Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions Drug Metab. Dispos. 25 1157 1164 1:CAS:528:DyaK2sXmvVWnsLg%3D 9321519
26. K. Tanaka I. Imoto J. Inoue K. Kozaki H. Tsuda Y. Shimada S. Aiko Y. Yoshizumi T. Iwai T. Kawano J. Inazawa 2007 Frequent methylation-associated silencing of a candidate tumorsuppressor, CRABP1, in esophageal squamous-cell carcinoma Oncogene 26 6456 6468 1:CAS:528:DC%2BD2sXhtV2is73E 10.1038/sj.onc.1210459 17438526 (Pubitemid 47494215)
27. A. Tong H. Zhang Z. Li L. Gou Z. Wang H. Wei M. Tang S. Liang L. Chen C. Huang Y. Wei 2007 Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid Cancer Chemother. Pharmacol. 61 791 802 10.1007/s00280-007-0536-2 17593366
28. D. Vimalachandran E. Costello 2004 Proteomic technologies and their application to pancreatic cancer Expert Rev. Proteomics 1 493 501 1:CAS:528:DC%2BD2cXhtVyqtr3L 10.1586/14789450.1.4.493 15966844 (Pubitemid 43826414)
29. G. Watanabe S. Kato H. Nakata T. Ishida N. Ohuchi C. Ishioka 2009 alphaB-crystallin: a novel p53-target gene required for p53-dependent apoptosis Cancer Sci. 100 2368 2375 1:CAS:528:DC%2BD1MXhsFOltrnM 10.1111/j.1349-7006.2009. 01316.x 19799611
30. D. H. Yu 1998 The role of oncogenes in drug resistance Cytotechnology 27 283 292 1:CAS:528:DyaK1MXhtFyrsLc%3D 10.1023/A:1008053913764 19002799
31. H. Zeng G. Liu P. A. Rea G. D. Kruh 2000 Transport of amphipathic anions by human multidrug resistance protein 3 Cancer Res. 60 4779 4784 1:CAS:528:DC%2BD3cXmsFWhs74%3D 10987286